Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 5
1996 8
1997 16
1998 30
1999 34
2000 26
2001 49
2002 60
2003 45
2004 37
2005 15
2006 29
2007 23
2008 27
2009 29
2010 38
2011 45
2012 64
2013 71
2014 56
2015 80
2016 81
2017 77
2018 72
2019 95
2020 87
2021 76
2022 60
2023 60
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

1,265 results

Results by year

Filters applied: . Clear all
Page 1
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S, Ikegami M, Koyama T, Sunami K, Ogata D, Kage H, Yanagaki M, Ikeuchi H, Ueno T, Tanikawa M, Oda K, Osuga Y, Mano H, Kohsaka S. Mizuno S, et al. Mol Cancer Ther. 2023 Feb 1;22(2):227-239. doi: 10.1158/1535-7163.MCT-22-0302. Mol Cancer Ther. 2023. PMID: 36442478 Free PMC article.
Activating mutations in mitogen-activated protein kinase kinase 1 (MAP2K1) are involved in a variety of cancers and may be classified according to their RAF dependence. Sensitivity to combined BRAF and MEK treatments is associated with co-mutations of MAP2K1 …
Activating mutations in mitogen-activated protein kinase kinase 1 (MAP2K1) are involved in a variety of cancers and may be cla …
Acquired Resistance to KRAS(G12C) Inhibition in Cancer.
Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. Awad MM, et al. N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281. N Engl J Med. 2021. PMID: 34161704 Free PMC article.
BACKGROUND: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRAS(G12C)). ...RESULTS: A total of 38 patients were included in this study: 27 with …
BACKGROUND: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS gl …
Rare molecular subtypes of lung cancer.
Harada G, Yang SR, Cocco E, Drilon A. Harada G, et al. Nat Rev Clin Oncol. 2023 Apr;20(4):229-249. doi: 10.1038/s41571-023-00733-6. Epub 2023 Feb 20. Nat Rev Clin Oncol. 2023. PMID: 36806787 Free PMC article. Review.
Oncogenes that occur in 5% of non-small-cell lung cancers have been defined as 'rare'; nonetheless, this frequency can correspond to a substantial number of patients diagnosed annually. ...In tandem, the number of approved targeted therapies for patients with rare molecula …
Oncogenes that occur in 5% of non-small-cell lung cancers have been defined as 'rare'; nonetheless, this frequency can correspond to …
Anticancer drug resistance: An update and perspective.
Nussinov R, Tsai CJ, Jang H. Nussinov R, et al. Drug Resist Updat. 2021 Dec;59:100796. doi: 10.1016/j.drup.2021.100796. Epub 2021 Dec 16. Drug Resist Updat. 2021. PMID: 34953682 Free PMC article. Review.
For example, the common KRas(G12C) driver mutation emerges in different cancers. Most occur in NSCLC, but some occur, albeit to a lower extent, in colorectal cancer and pancreatic ductal carcinoma. The responses to KRas(G12C) inhibitors are variable and fall into th …
For example, the common KRas(G12C) driver mutation emerges in different cancers. Most occur in NSCLC, but some occur, albeit to a low …
Recurrent Somatic MAP2K1 Mutations in Papillary Thyroid Cancer and Colorectal Cancer.
Bu R, Siraj AK, Masoodi T, Parvathareddy SK, Iqbal K, Al-Rasheed M, Haqawi W, Diaz M, Victoria IG, Aldughaither SM, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. Bu R, et al. Front Oncol. 2021 May 11;11:670423. doi: 10.3389/fonc.2021.670423. eCollection 2021. Front Oncol. 2021. PMID: 34046359 Free PMC article.
MAP2K1 mutations have been identified in several cancers. However, their role in Middle Eastern papillary thyroid cancer (PTC) and colorectal cancer (CRC) is lacking. ...We further analyzed 286 PTC and 289 CRC MAPK wildtype cases and found three MAP …
MAP2K1 mutations have been identified in several cancers. However, their role in Middle Eastern papillary thyroid cancer …
Cancer-causing MAP2K1 mutation in a mosaic patient with cardio-facio-cutaneous syndrome and immunodeficiency.
Zakharova V, Raykina E, Mersiyanova I, Deordieva E, Pershin D, Vedmedskia V, Rodina Y, Kuzmenko N, Maschan M, Shcherbina A. Zakharova V, et al. Hum Mutat. 2022 Dec;43(12):1852-1855. doi: 10.1002/humu.24463. Epub 2022 Sep 12. Hum Mutat. 2022. PMID: 36054331
It is thought that germline cancer-causing mutations would be embryonic lethal, as a more severe phenotype was shown in Drosophila and zebrafish embryos with cancer MAP2K1 mutations than in those with RASopathy mutations. Here we report the case of a patient …
It is thought that germline cancer-causing mutations would be embryonic lethal, as a more severe phenotype was shown in Drosophila an …
MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer.
Tian Y, Chen ZH, Wu P, Zhang D, Ma Y, Liu XF, Wang X, Ding D, Cao XC, Yu Y. Tian Y, et al. Adv Sci (Weinh). 2023 Apr;10(12):e2204819. doi: 10.1002/advs.202204819. Epub 2023 Feb 23. Adv Sci (Weinh). 2023. PMID: 36815359 Free PMC article.
Tamoxifen is commonly used for the treatment of patients with estrogen receptor-positive (ER+) breast cancer, but the acquired resistance to tamoxifen presents a critical challenge of breast cancer therapeutics. Recently, long noncoding RNA MIR497HG and its embedded …
Tamoxifen is commonly used for the treatment of patients with estrogen receptor-positive (ER+) breast cancer, but the acquired resist …
Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J, Dai X, Bianchi A, De Castro Silva I, Mehra S, Garrido VT, Lamichhane P, Singh SP, Zhou Z, Dosch AR, Messaggio F, Ban Y, Umland O, Hosein PJ, Nagathihalli NS, Merchant NB. Datta J, et al. Gastroenterology. 2022 Dec;163(6):1593-1612. doi: 10.1053/j.gastro.2022.07.076. Epub 2022 Aug 7. Gastroenterology. 2022. PMID: 35948109 Free PMC article.
BACKGROUND & AIMS: We have shown that reciprocally activated rat sarcoma (RAS)/mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) and Janus kinase/signal transducer and activator of transcription 3 (STAT3) pathways mediate therapeutic resistance in p …
BACKGROUND & AIMS: We have shown that reciprocally activated rat sarcoma (RAS)/mitogen-activated protein kinase/extracellular signal-reg …
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Rambow F, et al. Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12. Cell. 2018. PMID: 30017245 Free article.
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. ...
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD) …
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Liu T, Oberley M, Spetzler D, Korn WM, Shen L, Lenz HJ. Wang J, et al. Lancet Oncol. 2023 Feb;24(2):151-161. doi: 10.1016/S1470-2045(22)00783-5. Epub 2023 Jan 18. Lancet Oncol. 2023. PMID: 36681091 Free PMC article.
Antitumour immune response within the tumour environment was predicted by analysing the infiltration of immune cells and immune signatures using The Cancer Genome Atlas database. The Kaplan-Meier method and the log-rank test were used to evaluate the impact of gene alterat …
Antitumour immune response within the tumour environment was predicted by analysing the infiltration of immune cells and immune signatures u …
1,265 results